Sylvain joined Dexcom in 2018 and became CFO in 2021. By expanding Sylvain's role, Dexcom has filled a vacancy created by the ...
On May 29, Goldman Sachs analyst David Roman initiated coverage DexCom Inc. (NASDAQ:DXCM) with a Buy rating and a price target of $104. The initiation is part of Goldman Sachs’s broader coverage ...
Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021.
Dexcom ( ) has issued an announcement. On September 10, 2026, Dexcom ’s board appointed Executive Vice President and Chief Financial Officer Jereme Sylvain to the expanded role ...
1d
Abbott Laboratories (ABT) vs. DexCom (DXCM) — A Thorough Comparison of Business Growth Potential
Will Abbott, which is expanding into comprehensive healthcare centered on FreeStyle Libre, or DexCom, which is aiming for high growth and high profitability as a CGM specialist, prevail?]Record Date: ...
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and ...
A company-specific look at DexCom, the current market theme surrounding DXCM, its operating relevance and the evidence needed to assess what follows.
DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...
DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...
Dexcom stock is listed on Nasdaq under the ticker DXCM, with the most recent completed regular session closing price of USD ...
Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...
Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. According to Dexcom, Sylvain has brough the combination of strategic judgment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results